EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

KRAS , NRAS , BRAF , and PIK3CA mutation rates, clinicopathological association, and their prognostic value in Iranian colorectal cancer patients

Zohreh Mirzapoor Abbasabadi, Dariush Hamedi Asl, Babak Rahmani, Rozhin Shahbadori, Sara Karami, Amir Peymani, Sara Taghizadeh, Fatemeh Samiee Rad

Journal of Clinical Laboratory Analysis · 2023

DOI: 10.1002/jcla.24868 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Laboratory Analysis, 2023. Verfasst von Zohreh Mirzapoor Abbasabadi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine, Faculty of Medical Sciences, Qazvin University of Medical Sciences, Qazvin, Iran. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Membrane Proteins, GTP Phosphohydrolases. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Grant-in-Aid for Scientific Research of Qazvin University of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Mutations in KRAS , NRAS , BRAF , and PIK3CA genes are critical factors in clinical evaluation of colorectal cancer (CRC) development and progression. In Iran, however, the data regarding genetic profile of CRC patients is limited except for KRAS exon2 and BRAF V600F mutations. This study aimed to investigate the mutational spectrum and prognostic effects of these genes and explore the relationship between these mutations and clinicopathological features of CRC.

Method

To achieve these objectives, mutations in KRAS (exons 2, 3, and 4), NRAS (exons 2, 3, and 4), PIK3CA (exons 9 and 20), and BRAF (exon 15) was determined using PCR and pyrosequencing in a total of 151 patients with colorectal cancer.

Results

KRAS , BRAF , NRAS , and PIK3CA mutations were identified in 41%, 5.96%, 3.97%, and 13.24% of the cases, respectively. There were some significant correlations between clinicopathological features and KRAS , PIK3CA , BRAF , and NRAS mutations. Mutations in KRAS and PIK3CA were shown to be independent risk factors for poor survival of the patients at stage I‐IV ( p < 0.0001 and p = 0.001, respectively). No significant impact on prognosis was observed in patients with BRAF mutations.

Conclusion

Our study revealed the prevalence of CRC biomarkers mutations in Iranian patients and emphasized the role of KRAS and PIK3CA on shorter overall survival rates in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsProto-Oncogene Proteins p21(ras)Membrane ProteinsGTP PhosphohydrolasesProto-Oncogene Proteins B-rafClass I Phosphatidylinositol 3-KinasesBiomarkers, TumorMutationPrognosisIranHumansMaleFemaleYoung AdultAdultMiddle AgedAgedAged, 80 and over

Stichwörter der Autor:innen

BRAFKRASNRASPIK3CAcolorectal cancer

Substanzen

KRAS protein, humanNRAS protein, humanBRAF protein, humanPIK3CA protein, humanProto-Oncogene Proteins p21(ras)Membrane ProteinsGTP PhosphohydrolasesProto-Oncogene Proteins B-rafClass I Phosphatidylinositol 3-KinasesBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Molecular Medicine, Faculty of Medical Sciences, Qazvin University of Medical Sciences, Qazvin, Iran.
  • Department of Pathology and Molecular Medicine, Behsotun Lab, Alborz University of Medical Sciences, Karaj, Iran.
  • Department of Pathology and Molecular Medicine, Mehr Lab, Alborz University of Medical Sciences, Hashtgerd, Iran.
  • Medical Microbiology Research Center, Qazvin University of Medical Sciences, Qazvin, Iran.
  • Translational Ophthalmology Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.
  • Department of Pathology, Qazvin University of Medical Sciences, Qazvin, Iran.

Förderung

  • Grant-in-Aid for Scientific Research of Qazvin University of Medical Sciences

Zitieren

APA

Mirzapoor Abbasabadi, Z., Hamedi Asl, D., Rahmani, B., Shahbadori, R., Karami, S., Peymani, A., Taghizadeh, S., & Samiee Rad, F. (2023). KRAS , NRAS , BRAF , and PIK3CA mutation rates, clinicopathological association, and their prognostic value in Iranian colorectal cancer patients. Journal of Clinical Laboratory Analysis. https://doi.org/10.1002/jcla.24868

Vancouver

Mirzapoor Abbasabadi Z, Hamedi Asl D, Rahmani B, Shahbadori R, Karami S, Peymani A, et al. KRAS , NRAS , BRAF , and PIK3CA mutation rates, clinicopathological association, and their prognostic value in Iranian colorectal cancer patients. Journal of Clinical Laboratory Analysis. 2023. doi:10.1002/jcla.24868

BibTeX
@article{MirzapoorAbbasabadi2023,
  author = {Mirzapoor Abbasabadi, Zohreh and Hamedi Asl, Dariush and Rahmani, Babak and Shahbadori, Rozhin and Karami, Sara and Peymani, Amir and Taghizadeh, Sara and Samiee Rad, Fatemeh},
  title = {KRAS , NRAS , BRAF , and PIK3CA mutation rates, clinicopathological association, and their prognostic value in Iranian colorectal cancer patients},
  journal = {Journal of Clinical Laboratory Analysis},
  year = {2023},
  doi = {10.1002/jcla.24868}
}
Kostenlos starten →